Literature DB >> 19338581

Interaction of benzylidene-anabaseine analogues with agonist and allosteric sites on muscle nicotinic acetylcholine receptors.

H R Arias1, H Xing, K Macdougall, M P Blanton, F Soti, W R Kem.   

Abstract

BACKGROUND AND
PURPOSE: Benzylidene-anabaseines (BAs) are partial agonists of the alpha7 nicotinic acetylcholine receptor (nAChR) but their mechanism(s) of action are unknown. Our study explores several possibilities, including direct interactions of BAs with the nAChR channel. EXPERIMENTAL APPROACH: Functional and radioligand-binding assays were used to examine the interaction of two BA analogues, 3-(2,4-dimethoxybenzylidene)-anabaseine (DMXBA) and its primary metabolite 3-(4-hydroxy-2-methoxybenzylidene)-anabaseine (4OH-DMXBA) with both agonist and non-competitive antagonist (NCA)-binding sites on muscle-type nAChRs. KEY
RESULTS: Both BAs non-competitively inhibited ACh activation of human fetal muscle nAChRs and sterically inhibited the specific binding of the NCAs [piperidyl-3,4-3H(N)]-(N-(1-(2-thienyl)cyclohexyl)-3,4-piperidine ([(3)H]TCP) and [(3)H]dizocilpine to Torpedo nAChRs in the desensitized state. These compounds modulated [(3)H]tetracaine, [(14)C]amobarbital and [(3)H]TCP binding to resting nAChRs by allosteric mechanisms. Both BAs enhanced [(3)H]TCP binding when the nAChR was initially in the resting but activatable state, suggesting that both compounds desensitized the Torpedo nAChR. Although DMXBA failed to activate human fetal muscle nAChRs, 4OH-DMXBA was found to be a partial agonist. [(3)H]Nicotine competition-binding experiments confirmed that 4OH-DMXBA has higher affinity than DMXBA for the agonist sites, and that DMXBA is also a competitive antagonist. CONCLUSIONS AND IMPLICATIONS: 3-(4-hydroxy-2-methoxybenzylidene)-anabaseine is a partial agonist for human fetal muscle nAChRs, whereas DMXBA only has competitive and NCA activities. The NCA-binding site for BAs overlaps both the phencyclidine- and dizocilpine-binding sites in the desensitized Torpedo nAChR ion channel. The desensitizing property of BAs suggests another possible mode of non-competitive inhibition in addition to direct channel-blocking mechanisms.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19338581      PMCID: PMC2697798          DOI: 10.1111/j.1476-5381.2009.00156.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  43 in total

1.  Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.

Authors:  Ann Olincy; Josette G Harris; Lynn L Johnson; Vicki Pender; Susan Kongs; Diana Allensworth; Jamey Ellis; Gary O Zerbe; Sherry Leonard; Karen E Stevens; James O Stevens; Laura Martin; Lawrence E Adler; Ferenc Soti; William R Kem; Robert Freedman
Journal:  Arch Gen Psychiatry       Date:  2006-06

Review 2.  Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors.

Authors:  Hugo R Arias; Pankaj Bhumireddy
Journal:  Curr Protein Pept Sci       Date:  2005-10       Impact factor: 3.272

Review 3.  Molecular mechanisms and binding site locations for noncompetitive antagonists of nicotinic acetylcholine receptors.

Authors:  Hugo R Arias; Pankaj Bhumireddy; Cecilia Bouzat
Journal:  Int J Biochem Cell Biol       Date:  2006-02-20       Impact factor: 5.085

4.  Metabolism and disposition of GTS-21, a novel drug for Alzheimer's disease.

Authors:  R Azuma; M Komuro; B H Korsch; J C Andre; O Onnagawa; S R Black; J M Mathews
Journal:  Xenobiotica       Date:  1999-07       Impact factor: 1.908

5.  The correction of alpha7 nicotinic acetylcholine receptor concentration-response relationships in Xenopus oocytes.

Authors:  R L Papke; J S Thinschmidt
Journal:  Neurosci Lett       Date:  1998-11-13       Impact factor: 3.046

6.  Pharmacokinetics and urinary excretion of DMXBA (GTS-21), a compound enhancing cognition.

Authors:  V Mahnir; B Lin; K Prokai-Tatrai; W R Kem
Journal:  Biopharm Drug Dispos       Date:  1998-04       Impact factor: 1.627

7.  Photoaffinity labeling the torpedo nicotinic acetylcholine receptor with [(3)H]tetracaine, a nondesensitizing noncompetitive antagonist.

Authors:  R E Middleton; N P Strnad; J B Cohen
Journal:  Mol Pharmacol       Date:  1999-08       Impact factor: 4.436

8.  Identification of amino acids of the torpedo nicotinic acetylcholine receptor contributing to the binding site for the noncompetitive antagonist [(3)H]tetracaine.

Authors:  M J Gallagher; J B Cohen
Journal:  Mol Pharmacol       Date:  1999-08       Impact factor: 4.436

9.  Relative toxicities and neuromuscular nicotinic receptor agonistic potencies of anabasine enantiomers and anabaseine.

Authors:  Stephen T Lee; Kristin Wildeboer; Kip E Panter; William R Kem; Dale R Gardner; Russell J Molyneux; Cheng-Wei Tom Chang; Ferenc Soti; James A Pfister
Journal:  Neurotoxicol Teratol       Date:  2006-02-20       Impact factor: 3.763

10.  Molecular mechanisms and binding site location for the noncompetitive antagonist crystal violet on nicotinic acetylcholine receptors.

Authors:  Hugo R Arias; Pankaj Bhumireddy; Guillermo Spitzmaul; James R Trudell; Cecilia Bouzat
Journal:  Biochemistry       Date:  2006-02-21       Impact factor: 3.162

View more
  2 in total

1.  Non-competitive Inhibition of Nicotinic Acetylcholine Receptors by Ladybird Beetle Alkaloids.

Authors:  Ron L Leong; Hong Xing; Jean-Claude Braekman; William R Kem
Journal:  Neurochem Res       Date:  2014-11-05       Impact factor: 3.996

Review 2.  Insights Into Nicotinic Receptor Signaling in Nicotine Addiction: Implications for Prevention and Treatment.

Authors:  Wuyi Liu; Ming D Li
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.